Tianjin Ringpu Bio-Technology Co.,Ltd. (SHE:300119)

SHE:300119 Revenue

Tianjin Ringpu Bio-Technology had revenue of 950.05M CNY in the quarter ending September 30, 2026, with 13.54% growth. This brings the company's total for the last twelve months to 3.52B, up 4.51% year-over-year. In the year 2025, Tianjin Ringpu Bio-Technology had annual revenue of 3.40B with 10.70% growth. That makes Tianjin Ringpu Bio-Technology the 10,962nd largest company in the world by revenue and 1,837th in China.

• Revenue (ttm): 3.52B
• Revenue Growth: +4.51%
• P/S Ratio: 2.12
• Revenue / Employee: 1.26M
• Employees: 2,803
• Market Cap: 7.45B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Veterinary Biological Products 1.47B 43.4%
• Pharmaceutical Preparations and Active Pharmaceutical Ingredients 1.05B 30.9%
• Pet Supply Chain 781.78M 23.0%
• Epidemic Control Services 69.99M 2.1%
• Other 21.78M 0.6%

By Geography

Chart

• Eastern Region 998.69M 29.4%
• Southern Region 623.52M 18.3%
• Northern Region 575.10M 16.9%
• Central China 416.30M 12.2%
• Northeast District 281.00M 8.3%
• Southwest District 267.54M 7.9%
• Export 126.73M 3.7%
• North-West Area 109.57M 3.2%

Fiscal year ended Dec 31, 2025 See the full SHE:300119 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.40B	328.53M	10.70%
Dec 31, 2024	3.07B	360.83M	13.32%
Dec 31, 2023	2.71B	624.85M	29.98%
Jan 1, 2023	2.08B	77.11M	3.84%
Jan 1, 2022	2.01B	6.73M	0.34%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error